Harmony Biosciences, a Plymouth Meeting-based pharmaceutical company that develops and commercializes therapies for people living with rare neurological disorders, officially went public this week.

The company said on Tuesday that the pricing of its upsized initial public offering of 5,348,837 shares of common stock would be be $24.00 per share.

“The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Harmony, are expected to be $128.4 million,” the company said in a press release.

READ FULL ARTICLE HERE